<scp>First‐in‐human</scp> study of <scp>JNJ</scp>‐63709178, a <scp>CD123</scp>/<scp>CD3</scp> targeting antibody, in relapsed/refractory acute myeloid leukemia
Michael Boyiadzis(UPMC Hillman Cancer Center), Juan Manuel Alonso‐Domínguez(Hospital Universitario Fundación Jiménez Díaz), Jay Yang(Boston Children's Hospital), William B. Donnellan(Sarah Cannon), Lucille Ferrante(Johnson & Johnson (United States)), Michael R. Grunwald(Levine Cancer Institute), Christina Guttke(Johnson & Johnson (United States)), Trevor Tucker(Janssen (United States)), Pinkal Desai(NewYork–Presbyterian Hospital), Xiaoying Xu(Janssen (United States)), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Josè Antonio Pérez-Simón(Instituto de Biomedicina de Sevilla), Nikki Daskalakis(Johnson & Johnson (United States)), Xiang Li(Janssen (United States)), Olga Salamero(Vall d'Hebron Institut de Recerca)
Cited by 35
Related Papers
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression
|JAMA Psychiatry|2019|780
Somatic mutations precede acute myeloid leukemia years before diagnosis
|Nature Medicine|2018|621
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
|Cancer Discovery|2018|570
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
Ibrutinib and Venetoclax for First-Line Treatment of CLL
|New England Journal of Medicine|2019|502